Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

20112,805 citationsJournal Articlebronze Open Access

Authors

José Baselga · Massachusetts General Hospital

Mario Campone · Institut de Cancérologie de l'Ouest

Martine Piccart · Institut Jules Bordet

Howard A. Burris

Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center

Tarek Sahmoud · Novartis (United States)

Shinzaburo Noguchi · Osaka University

Abstract

Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. (Funded by Novartis; BOLERO-2 ClinicalTrials.gov number, NCT00863655.).

Topics & Keywords

PI3K/AKT/mTOR signaling in cancer Cancer Treatment and Pharmacology Estrogen and related hormone effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 6, pp. 520-529

DOI: 10.1056/nejmoa1109653

Field-Weighted Citation Impact: 95.92